Back to Browse Journals » Psoriasis: Targets and Therapy » Volume 2

Psoriasis: epidemiology, natural history, and differential diagnosis

Authors Basko-Plluska JL, Petronic-Rosic V

Published Date September 2012 Volume 2012:2 Pages 67—76

DOI http://dx.doi.org/10.2147/PTT.S24009

Received 30 May 2012, Accepted 16 July 2012, Published 11 September 2012

Juliana L Basko-Plluska, Vesna Petronic-Rosic

Department of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, USA

Abstract: Psoriasis is a chronic, immune-mediated, inflammatory disease which affects primarily the skin and joints. It occurs worldwide, but its prevalence varies considerably between different regions of the world. Genetic susceptibility as well as environmental factors play an important role in determining the development and prognosis of psoriasis. Genome-wide association studies have identified many genetic loci as potential psoriasis susceptibility regions, including PSORS1 through PSORS7. Histocompatibility antigen (HLA) studies have also identified several HLA antigens, with HLA-Cw6 being the most frequently associated antigen. Epidemiological studies identified several modifiable risk factors that may predispose individuals to developing psoriasis or exacerbate pre-existing disease. These include smoking, obesity, alcohol consumption, diet, infections, medications and stressful life events. The exact mechanism by which they trigger psoriasis remains to be elucidated; however, existing data suggest that they are linked through Th1-mediated immunological pathways. The natural history of psoriasis varies depending on the clinical subtype as well as special circumstances, including pregnancy and HIV infection. In general, psoriasis is a chronic disease with intermittent remissions and exacerbations. The differential diagnosis is vast and includes many other immune-mediated, inflammatory disorders.

Keywords: psoriasis, epidemiology, natural history, differential diagnosis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

Psoriasis in childhood: effective strategies to improve treatment adherence

Shah KN, Cortina S, Ernst MM, Kichler JC

Psoriasis: Targets and Therapy 2015, 5:43-54

Published Date: 16 March 2015

Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study

Narayanan S, Guyatt V, Franceschetti A, Hautamaki EL

Psoriasis: Targets and Therapy 2015, 5:1-7

Published Date: 23 December 2014

Epidemiology and treatment of psoriasis: a Chinese perspective

Pan R, Zhang JZ

Psoriasis: Targets and Therapy 2014, 4:37-47

Published Date: 13 October 2014

Self-management in patients with psoriasis

Pathak SN, Scott PL, West C, Feldman SR

Psoriasis: Targets and Therapy 2014, 4:19-26

Published Date: 10 July 2014

Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy

Flatz L, Conrad C

Psoriasis: Targets and Therapy 2013, 3:1-10

Published Date: 27 February 2013

Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis

Molteni S, Reali E

Psoriasis: Targets and Therapy 2012, 2:55-66

Published Date: 4 September 2012

Quality of life issues and measurement in patients with psoriasis

Tan X, Feldman SR, Balkrishnan R

Psoriasis: Targets and Therapy 2012, 2:13-23

Published Date: 21 February 2012

Psoriasis and cardiovascular disease: epidemiology, mechanisms, and clinical implications

Pearson KC, Armstrong AW

Psoriasis: Targets and Therapy 2012, 2:1-11

Published Date: 13 January 2012

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009